Compare Bristol-Myers Squibb Co (BMY) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Under Armour Inc Class A — how do they compare? Bristol-Myers Squibb Co trades at $58.7 (market cap $116.30B), while Under Armour Inc Class A trades at $6.73 (market cap $2.79B). The key difference: Bristol-Myers Squibb Co is far larger — about 41.7× Under Armour Inc Class A's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| BMY | UA | |
|---|---|---|
Market Cap | $116.30B | $2.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $7.88 |
52-Week Low | $42.60 | $3.96 |
Enterprise Value | $152.24B | $4.42B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Under Armour (UA) trades at $6.61 with a neutral daily performance. The stock shows bullish technical signals from moving averages but faces fundamental challenges with negative net income margins (-9.98%) and declining revenue projections for 2026. Recent earnings showed mixed results with a Q1 2026 miss, while analyst sentiment remains divided with 40.3% buy ratings. The company's cash flow trends show significant outflows, with net cash flow negative $361.87 million in 2025.
The outlook remains cautious due to ongoing revenue declines and profitability challenges, though technical strength and institutional buying by investors like Prem Watsa provide some support. Key risks include sustained negative earnings, competitive pressures, and execution of the company's turnaround strategy. The stock presents a speculative opportunity for investors believing in management's premium product focus and inventory discipline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
